Dillon Yeager
Psychiatric/Mental Health · Philipsburg, PANPI 1780357889
Payments from drug & device makers
Across 191 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$689
- AbbVie$629
- Otsuka America Pharmaceutical, Inc.$538
- Johnson & Johnson$384
- Neurocrine Biosciences, Inc.$270
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$263
- plus $980 from 12 others
What the payments were for
- Food & beverage$3,64497%
- Education$1093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 33 | $689 |
| AbbVie | 40 | $629 |
| Otsuka America Pharmaceutical, Inc. | 25 | $538 |
| Johnson & Johnson | 16 | $384 |
| Neurocrine Biosciences, Inc. | 15 | $270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $263 |
| Vanda Pharmaceuticals Inc. | 7 | $168 |
| Supernus Pharmaceuticals, Inc. | 5 | $167 |
| Axsome Therapeutics, Inc. | 9 | $161 |
| Lundbeck LLC | 10 | $161 |
| Alkermes, Inc. | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Indivior Inc. | 3 | $60 |
| Sage Therapeutics, LLC | 2 | $34 |
| AstraZeneca | 1 | $25 |
| Novo Nordisk | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $10 |
How this compares
$3,753 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 57 | $81,884 |
| RexultiBrexpiprazole | 13 | $19,638 |
| Bupropion XlBupropion Hcl | 47 | $1,286 |
| Fluoxetine Hcl | 20 | $1,092 |
| Lurasidone Hcl | 15 | $751 |
| Buspirone Hcl | 43 | $719 |
| Vilazodone Hcl | 12 | $692 |
| Clonazepam | 75 | $686 |
| Lamotrigine | 66 | $643 |
| Mirtazapine | 34 | $558 |
| Propranolol Hcl | 17 | $495 |
| Aripiprazole | 19 | $420 |
| Trazodone Hcl | 38 | $372 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $344 |
| Duloxetine Hcl | 17 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $629 | $81,88457 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $538 | $19,63813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Philipsburg
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.